Emerge Diagnostics Receives FDA 510(k) Clearance for Wireless Device
Tulsa, OK, September 23, 2013 --(PR.com)-- Emerge Diagnostics is pleased to announce that it has
received the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its wireless device,
The new clearance will allow for expansion of the EFA technology. The wireless ability will streamline
the assessment process as well as create other efficiencies with its advanced capabilities.
“Emerge has set the industry standard for soft tissue diagnostics. Our wireless technology will bring an
unprecedented level of innovation to this industry. This is a major milestone for Emerge Diagnostics,”
said Jerry W. Wilkins, CEO of Emerge Diagnostics.
About Emerge Diagnostics
Emerge Diagnostics is the provider of the Electrodiagnostic Functional Assessment, EFA and
EFA-STM©. The EFA-Soft Tissue Management (EFA-STM) program is a bookend solution that
compares pre and post-loss data and is a recommended best practice to accurately distinguish
compensable workplace injuries and/or exacerbation of pre-existing injuries from chronic, unrelated
conditions. In addition, employees receive better treatment for compensable conditions. For more about
Emerge Diagnostics, please visit our website at www.emergedx.com.
Contact via Email
Online Version of Press Release:
You can read the online version of this press release at: http://www.pr.com/press-release/517518